Sodium glucose cotransport-2 inhibition and intrarenal RAS activity in people with type 1 diabetes-Reference-Cited by-同舟云学术

Sodium glucose cotransport-2 inhibition and intrarenal RAS activity in people with type 1 diabetes

Published:2014-11 Issue:5 Volume:86 Page:1057-1058
ISSN:0085-2538
Container-title:Kidney International
language:en
Short-container-title:Kidney International

Author:

Cherney David Z.I.,Perkins Bruce A.,Soleymanlou Nima,Xiao Fengxia,Zimpelmann Joseph,Woerle Hans-Juergen,E Johansen Odd,Broedl Uli C.,von Eynatten Maximilian,Burns Kevin D.

Publisher

Elsevier BV

Subject

Nephrology

Reference4 articles.

1. Sodium-glucose linked transporter-2 inhibitors: potential for renoprotection beyond blood glucose lowering?;Gilbert,2013

2. A nephrologist’s point of view on sodium-glucose linked transporter-2 inhibitors: not all that glitters is gold;Musetti;Kidney Int,2014

3. The renal hemodynamic effect of SGLT2 inhibition in patients with type 1 diabetes;Cherney;Circulation,2014

4. Increased urinary angiotensin-converting enzyme 2 in renal transplant patients with diabetes;Xiao;PLoS One,2012

Cited by 100 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effects of SGLT2 inhibitors on parameters of renal venous congestion in intrarenal Doppler ultrasonography;Clinical Kidney Journal;2024-08-14

2. Plasma angiotensin-converting enzyme 2 (ACE2) is a marker for renal outcome of diabetic kidney disease (DKD) (U-CARE study 3);BMJ Open Diabetes Research & Care;2024-05

3. Why have SGLT2 Inhibitors Failed to Achieve the Desired Success in COVID-19?;Current Pharmaceutical Design;2024-04

4. Solution is not simple; sodium-glucose cotransporter-2 inhibitor use in Conn syndrome;Blood Pressure Monitoring;2024-03-11

5. Ketone production and excretion even during mild hyperglycemia and the impact of sodium-glucose co-transporter inhibition in type 1 diabetes;Diabetes Research and Clinical Practice;2024-01